Antitumor activity of methoxymorpholinyl doxorubicin: Potentiation by cytochrome P450 3A metabolism

Molecular Pharmacology

Volumn 67, Issue 1, 2005, Pages 212-219

  Lu, Hong ^a   Waxman, David J ^a  

^a Boston University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; CYTOCHROME P450 3A2; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; DOXORUBICIN DERIVATIVE; GLYCOPROTEIN P; NEMORUBICIN; OXYGENASE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHO CELL; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DRUG POTENTIATION; DRUG RESISTANCE; ENZYME ACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TUMOR CELL DESTRUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOCHROME P-450 CYP3A; DOXORUBICIN; GLIOSARCOMA; HALF-LIFE; KINETICS; MALE; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 11244311919     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.005371     Document Type: Article

References (39)

1. Alvino E, Gilberti S, Cantagallo D, Massoud R, Gatteschi A, Tentori L, Bonmassar E, and D'Atri S (1997) In vitro antitumor activity of 3′-desamino-3′(2-methoxy-4-morpholinyl) doxorubicin on human melanoma cells sensitive or resistant to triazene compounds. Cancer Chemother Pharmacol 40:180-184.
2. Bakker M, Droz JP, Hanauske AR, Verweij J, van Oosterom AT, Groen HJ, Pacciarini MA, Domenigoni L, van Weissenbruch F, Pianezzola E, et al. (1998) Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients. Br J Cancer 77:139-146.
3. Bakker M, Renes J, Groenhuijzen A, Visser P, Timmer-Bosscha H, Muller M, Groen HJ, Smit EF, and de Vries EG (1997) Mechanisms for high methoxymorpholino doxorubicin cytotoxicity in doxorubicin-resistant tumor cell lines. Int J Cancer 73:362-366.
4. Baldwin A, Huang Z, Jounaidi Y, and Waxman DJ (2003) Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer. Arch Biochem Biophys 409:197-206.
5. Beulz-Riche D, Robert J, Menard C, and Ratanasavanh D (2001) Metabolism of methoxymorpholino-doxorubicin in rat, dog and monkey liver microsomes: comparison with human microsomes. Fundam Clin Pharmacol 15:373-378.
6. Beulz-Riche D, Robert J, Riche C, and Ratanasavanh D (2002) Effects of paclitaxel, cyclophosphamide, ifosfamide, tamoxifen and cyclosporine on the metabolism of methoxymorpholinodoxorubicin in human liver microsomes. Cancer Chemother Pharmacol 49:274-280.
7. Breda M, Benedetti MS, Battaglia R, Castelli MG, Poggesi I, Spinelli R, Hackett AM, and Dostert P (2000) Species-differences in disposition and reductive metabolism of methoxymorpholinodoxorubicin (PNU 152243), a new potential anticancer agent. Pharmacol Res 41:239-248.
8. Chen G and Waxman DJ (1995) Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance. J Pharmacol Exp Ther 274:1271-1277.
9. Chen L and Waxman DJ (2002) Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer. Curr Pharm Des 8:1405-1416.
10. Danesi R, Agen C, Grandi M, Nardini V, Bevilacqua G, and Del Tacca M (1993) 3′-Deamino-3′-(2-methoxy-4-morpholmyl)-doxorubicin (FCE 23762): a new anthracycline derivative with enhanced cytotoxicity and reduced cardiotoxicity. Eur J Cancer 29A:1560-1565.
11. Ding S, Yao D, Burchell B, Wolf CR, and Friedberg T (1997) High levels of recombinant CYP3A4 expression in Chinese hamster ovary cells are modulated by coexpressed human P450 reductase and hemin supplementation. Arch Biochem Biophys 348:403-410.
12. Duran GE, Lau DH, Lewis AD, Kuhl JS, Bammler TK, and Sikic BI (1996) Differential single- versus double-strand DNA breakage produced by doxorubicin and its morpholinyl analogues. Cancer Chemother Pharmacol 38:210-216.
13. Fairchild CR, Ivy SP, Kao-Shan CS, Whang-Peng J, Rosen N, Israel MA, Melera PW, Cowan KH, and Goldsmith ME (1987) Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells. Cancer Res 47:5141-5148.
14. Fokkema E, Verweij J, van Oosterom AT, Uges DR, Spinelli R, Valota O, de Vries EG, and Groen HJ (2000) A prolonged methoxymorpholino doxorabicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study. Br J Cancer 82:767-771.
15. Geroni C, Pesenti E, Broggini M, Belvedere G, Tagliabue G, D'Incalci M, Pennella G, and Grandi M (1994) L1210 cells selected for resistance to methoxymorpholinyl doxorubicin appear specifically resistant to this class of morpholinyl derivatives. Br J Cancer 69:315-319.
16. Ghielmini M, Colli E, Bosshard G, Pennella G, Geroni C, Torri V, D'Incalci M, Cavalli F, and Sessa C (1998) Hematotoxicity on human bone marrow- and umbilical cord blood-derived progenitor cells and in vitro therapeutic index of methoxymorpholinyldoxorubicin and its metabolites. Cancer Chemother Pharmacol 42:235-240.
17. Iscan M, Klaavuniemi T, Coban T, Kapucuoglu N, Pelkonen O, and Raunio H (2001) The expression of cytochrome P450 enzymes in human breast tumours and normal breast tissue. Breast Cancer Res Treat 70:47-54.
18. Jounaidi Y (2002) Cytochrome P450-based gene therapy for cancer treatment: from concept to the clinic. Curr Drug Metab 3:609-622.
19. Kivisto KT, Griese EU, Fritz P, Linder A, Hakkola J, Raunio H, Beaune P, and Kroemer HK (1996) Expression of cytochrome P 450 3A enzymes in human lung: a combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumours. Naunyn Schmiedeberg's Arch Pharmacol 353:207-212.
20. Knupfer H, Knupfer MM, Hotfilder M, and Preise R (1999) P450-expression in brain tumors. Oncol Res 11:523-528.
21. Kuhl JS, Duran GE, Chao NJ, and Sikic BI (1993) Effects of the methoxymorpholino derivative of doxorubicin and its bioactivated form versus doxorubicin on human leukemia and lymphoma cell lines and normal bone marrow. Cancer Chemother Pharmacol 33:10-16.
22. Lau DH, Duran GE, Lewis AD, and Sikic BI (1994) Metabolic conversion of methoxymorpholinyl doxorubicin: from a DNA strand breaker to a DNA cross-linker. Br J Cancer 70:79-84.
23. Lau DH, Duran GE, and Sikic BI (1992) Characterization of covalent DNA binding of morpholino and cyanomorpholino derivatives of doxorubicin. J Natl Cancer Inst 84:1587-1592.
24. Lau DH, Lewis AD, and Sikic BI (1989) Association of DNA cross-linking with potentiation of the morpholino derivative of doxorubicin by human liver microsomes. J Natl Cancer Inst 81:1034-1038.
25. Lawrence TS, Rehemtulla A, Ng EY, Wilson M, Trosko JE, and Stetson PL (1998) Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-flucytosine. Cancer Res 58:2588-2593.
26. Lewis AD, Lau DH, Duran GE, Wolf CR, and Sikic BI (1992) Role of cytochrome P-450 from the human CYP3A gene family in the potentiation of morpholino doxorubicin by human liver microsomes. Cancer Res 52:4379-4384.
27. Martinez C, Garcia-Martin E, Pizarro RM, Garcia-Gamito FJ, and Agundez JA (2002) Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy. Br J Cancer 87:681-686.
28. Michieli M, Damiani D, Michelutti A, Melli C, Ermacora A, Geromin A, Fanin R, Russo D, and Baccarani M (1996) Overcoming PGP-related multidrug resistance. The cyclosporine derivative SDZ PSC 833 can abolish the resistance to methoxymorpholynil-doxorubicin. Haematologica 81:295-301.
29. Murray GI, McFadyen MC, Mitchell RT, Cheung YL, Kerr AC, and Melvin WT (1999) Cytochrome P450 CYP3A in human renal cell cancer. Br J Cancer 79:1836-1842.
30. Quintieri L, Rosato A, Napoli E, Sola F, Geroni C, Floreani M, and Zanovello P (2000) In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A. Cancer Res 60:3232-3238.
31. Ripamonti M, Pezzoni G, Pesenti E, Pastori A, Farao M, Bargiotti A, Suarato A, Spreafico F, and Grandi M (1992) In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells. Br J Cancer 65:703-707.
32. Ross WE, Glaubiger D, and Kohn KW (1979) Qualitative and quantitative aspects of intercalator-induced DNA strand breaks. Biochim Biophys Acta 562:41-50.
33. Scudder SA, Brown JM, and Sikic BI (1988) DNA cross-linking and cytotoxicity of the alkylating cyanomorpholino derivative of doxorubicin in multidrug-resistant cells. J Natl Cancer Inst 80:1294-1298.
34. Sessa C, Zucchetti M, Ghielmini M, Bauer J, D'Incalci M, de Jong J, Naegele H, Rossi S, Pacciarini MA, Domenigoni L, et al. (1999) Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243). Cancer Chemother Pharmacol 44:403-410.
35. Sinha BK, Haim N, Dusre L, Kerrigan D, and Pommier Y (1988) DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action. Cancer Res 48:5096-5100.
36. Suarato A, Angelucci F, and Geroni C (1999) Ring-B modified anthracyclines. Curr Pharm Des 5:217-227.
37. Sun Y, Li H, Lin Z, Sun L, Valota O, Battaglia R, and Pacciarini M (2003) Phase I and pharmacokinetic study of nemorubicin hydrochloride (methoxymorpholino doxorubicin; PNU-152243) administered with iodinated oil via hepatic artery (IHA) to patients (pt) with unresectable hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 22:361.
38. van der Graaf WT, Mulder NH, Meijer C, and de Vries EG (1995) The role of methoxymorpholino anthracycline and cyanomorpholino anthracycline in a sensitive small-cell lung-cancer cell line and its multidrug-resistant but P-glycoprotein-negative and cisplatin-resistant counterparts. Cancer Chemother Pharmacol 35:345-348.
39. Vasey PA, Bissett D, Strolin-Benedetti M, Poggesi I, Breda M, Adams L, Wilson P, Pacciarini MA, Kaye SB, and Cassidy J (1995) Phase I clinical and pharmacokinetic study of 3′-deamino-3′-(2-methoxy-4-morpholinyl) doxorubicin (FCE 23762). Cancer Res 55:2090-2096.